Breaking News

OSE Immunotherapeutics Receives Grant to Advance COVID-19 Vax

OSE’s research program aims to develop a prophylactic vaccine focused on memory T cells and based on a multiepitope-peptide approach.

By: Contract Pharma

Contract Pharma Staff

OSE Immunotherapeutics will receive a grant of up to €200,000 from Nantes Metropole, a community dedicated to the development of a prophylactic vaccine against the pandemic virus SARS-CoV-2. This funding was awarded as part of the Metropolitan Fund to Support Health Innovations Linked to the COVID-19 Health Crisis. OSE is working on the development of a prophylactic vaccine against the pandemic virus SARS-CoV-2. This research program aims to develop a prophylactic vaccine focused on memory T...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters